Temsirolimus for advanced renal cell carcinoma

Area of Science:

• Oncology
• Pharmacology

Background:

• Renal cell carcinoma (RCC) is a leading cancer with increasing incidence.
• Metastatic RCC (mRCC) carries a poor prognosis, with 25% of patients developing the advanced stage.
• Targeting the mTOR pathway has emerged as a viable treatment strategy for mRCC.

Purpose of the Study:

• To evaluate the efficacy of temsirolimus, an mTOR inhibitor, in treating metastatic renal cell carcinoma (mRCC).
• To assess the impact of temsirolimus on overall survival (OS) and progression-free survival (PFS) in various RCC subtypes and risk groups.

Main Methods:

• Review of pivotal Phase III trials comparing temsirolimus with interferon-alfa (IFN-α) and its combination.
• Analysis of second-line treatment data comparing temsirolimus with sorafenib in non-clear cell RCC.
• Examination of US FDA approval data for temsirolimus in advanced RCC.

Main Results:

• Temsirolimus demonstrated significant superiority in OS compared to IFN-α or combination therapy in poor-risk mRCC patients.
• The drug improved median survival by 3.6 months for poor prognosis patients.
• In second-line treatment for non-clear cell RCC, temsirolimus showed a relative PFS benefit compared to sorafenib, although median OS was lower.

Conclusions:

• Temsirolimus is an effective treatment option for advanced renal cell carcinoma, especially for poor-risk patients.
• Its efficacy extends to clear cell and papillary RCC subtypes.
• Temsirolimus received US FDA approval in 2007 for advanced RCC treatment.